Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 8MW2311 in advanced solid tumors
CTR20221428Phase 2Active
- Sponsor
- Maiwei Biotech
- Start
- Aug 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of 8MW2311 in Nonhematologic neoplasms, sponsored by Maiwei Biotech. Primary endpoints: All adverse events and Objective response rate. Started Aug 2022; status: active.
02
Drugs
8MW2311
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221428.